Influenza Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Test Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Influenza Diagnostics Market size was more than USD 1.9 billion in 2026 and is set to grow at a 5.51% CAGR between 2027 and 2036, crossing USD 3.25 billion by 2036. The industry revenue for 2027 is calculated at USD 1.99 billion.
Get more details on this report
Request Free Sample ReportInfluenza Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 34.66% market share in 2026, supported by advanced testing infrastructure, established laboratory networks, and routine use of rapid and molecular diagnostic technologies.
- Asia Pacific is projected to expand at a 6.67% CAGR as diagnostic capacity grows, testing adoption increases, and healthcare providers strengthen outbreak monitoring and patient triage practices.
Segment Momentum
- RIDT held a 32.73% market share in 2026 and remains the fastest-growing test type because it enables rapid clinical decision-making, immediate patient management, and efficient high-volume testing during influenza seasons.
- POCT is expanding fastest as healthcare increasingly requires rapid testing in decentralized settings, allowing quicker triage and reducing delays compared with traditional centralized diagnostic workflows.
Market Expansion Drivers
- Rising influenza burden and seasonal outbreaks increasing demand for rapid diagnostic testing solutions.
- Growing elderly and pediatric vulnerable populations driving early detection and testing adoption.
- Expanding government surveillance programs and global flu monitoring initiatives strengthening diagnostic uptake.
Leading Market Participants
- Top companies in the influenza diagnostics market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Becton, Dickinson and Company (United States), Hologic, Inc. (United States), QuidelOrtho Corporation (United States), DiaSorin S.p.A. (Italy), Sekisui Diagnostics, LLC (United States), Meridian Bioscience, Inc. (United States), bioMérieux SA (France).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.9 billion
- 2027 Estimated Market Size: USD 1.99 billion.
- Projected Market Size: USD 3.25 billion by 2036
- Growth Forecast: 5.51% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: RIDT (Test Type) | Hospitals (End Use)
- Emerging Opportunity Segment: RIDT (Test Type) | POCT (End Use)
Market Growth Drivers and Industry Trends
Rising influenza burden and seasonal outbreaks increasing demand for rapid diagnostic testing solutions
The influenza diagnostics market growth is being supported by the recurring burden of influenza infections and seasonal outbreaks that increase the need for timely disease identification. Healthcare providers rely on rapid diagnostic testing to distinguish influenza infections from other respiratory illnesses and support appropriate treatment and infection-control decisions. During periods of elevated transmission, laboratories, hospitals, clinics, and other healthcare settings require diagnostic solutions that can deliver results quickly while handling increased testing volumes. Greater awareness of influenza symptoms and the importance of early diagnosis is also encouraging patients and healthcare professionals to seek testing, particularly when respiratory disease activity rises.
Growing elderly and pediatric vulnerable populations driving early detection and testing adoption
A growing focus on protecting elderly individuals and children, who can be more vulnerable to complications from influenza, is strengthening influenza diagnostics market demand. Early identification allows healthcare professionals to assess infection more promptly and determine appropriate clinical management, particularly for patients with increased risks associated with respiratory illness. Pediatric and elderly care settings therefore require accessible diagnostic solutions that can support rapid decision-making without creating unnecessary delays in treatment. The need for reliable testing is further reinforced by healthcare systems seeking to distinguish influenza from other respiratory infections that may present with similar symptoms.
Expanding government surveillance programs and global flu monitoring initiatives strengthening diagnostic uptake
Government-led surveillance and coordinated influenza monitoring programs are increasing the role of diagnostic testing in tracking disease activity, supporting influenza diagnostics market expansion. Public health authorities depend on laboratory and point-of-care testing data to identify circulating influenza activity, monitor seasonal patterns, detect unusual transmission trends, and guide preparedness measures. Wider surveillance coverage requires healthcare facilities and laboratories to maintain diagnostic capabilities across different settings, including areas where disease monitoring infrastructure is being strengthened. Diagnostic information also supports public health decision-making by improving visibility into influenza circulation and helping authorities respond to changes in respiratory disease activity.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising influenza burden and seasonal outbreaks increasing demand for rapid diagnostic testing solutions | 2.00% | High | North America, Europe | High | Near Term |
| Growing elderly and pediatric vulnerable populations driving early detection and testing adoption | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Expanding government surveillance programs and global flu monitoring initiatives strengthening diagnostic uptake | 1.50% | High | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the influenza diagnostics market in 2026, accounting for 34.66% share, supported by advanced healthcare infrastructure, established laboratory networks, and strong emphasis on rapid infectious disease detection. Healthcare providers rely on timely diagnostic testing to guide treatment decisions, manage seasonal outbreaks, and support infection-control practices. Continued adoption of molecular and rapid diagnostic technologies is improving testing efficiency across hospitals, clinics, and diagnostic facilities. Strong public health preparedness and established testing capabilities further sustain regional demand for influenza diagnostic solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, driven by expanding healthcare access, increasing awareness of infectious disease detection, and strengthening diagnostic infrastructure. Growing investment in hospitals and laboratories is improving the availability of testing technologies across both urban and developing healthcare markets. Greater emphasis on early diagnosis and outbreak preparedness is also encouraging healthcare systems to expand their diagnostic capabilities. As demand for rapid and accessible infectious disease testing increases, influenza diagnostics are gaining broader application across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Lab-based diagnostic standardizationIn Germany, influenza diagnostics rely strongly on standardized laboratory-based testing protocols within structured healthcare networks. Hospitals and diagnostic labs emphasize high-accuracy molecular assays, with centralized systems supporting consistent reporting and surveillance integration across regional healthcare providers during seasonal influenza cycles.
France 🇫🇷
Public health screening relianceIn France, influenza diagnostics are strongly shaped by public health screening frameworks that support national surveillance and outbreak management. Healthcare providers focus on coordinated testing across hospitals and primary care, ensuring early identification of cases and alignment with seasonal vaccination and prevention programs.
Italy 🇮🇹
Seasonal outbreak detection systemsIn Italy, influenza diagnostics are primarily oriented toward managing recurring seasonal outbreaks through structured detection and reporting systems. Healthcare providers emphasize timely testing in hospitals and community clinics, supporting regional monitoring efforts and enabling responsive clinical management during peak influenza transmission periods.
Japan 🇯🇵
Aging population surveillance focusIn Japan, influenza diagnostics are closely linked to surveillance needs driven by an aging population highly susceptible to respiratory infections. Healthcare facilities emphasize early detection and routine testing in clinical settings, supporting public health monitoring and timely intervention during recurring seasonal outbreaks.
South Korea 🇰🇷
Digital health testing integrationIn South Korea, influenza diagnostics increasingly integrate with digital health systems that streamline test ordering, reporting, and outbreak tracking. Hospitals and clinics emphasize fast molecular and rapid antigen testing, supported by strong health IT infrastructure that enhances responsiveness during seasonal influenza activity.
United States 🇺🇸
Rapid respiratory testing adoptionIn the U.S., influenza diagnostics are driven by widespread adoption of rapid respiratory testing across hospitals, urgent care centers, and retail clinics. Healthcare providers prioritize quick turnaround diagnostics to differentiate influenza from other respiratory infections, supporting clinical decision-making during seasonal surges and integrated point-of-care testing adoption.
Segment Leadership and Growth Trends
Influenza Diagnostics Market Share (%), by Test Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTest Type Segment Analysis: RIDT (Largest & Fastest-Growing Segment)
Rapid influenza diagnostic tests (RIDTs) represented both the largest and fastest-growing test type in the influenza diagnostics market, accounting for a 32.73% share in 2026. Their strong position is supported by the need for rapid and accessible influenza screening, particularly where timely clinical decisions are important. RIDTs provide a practical diagnostic option in settings that require quick assessment without relying on more complex laboratory workflows. Growing emphasis on early identification of influenza infections, efficient patient management, and accessible diagnostic testing continues to support demand for rapid testing solutions across healthcare environments.
End Use Segment Analysis: Hospitals (Largest Segment) vs POCT (Fastest-Growing Segment)
Hospitals remained the largest end-use segment of the influenza diagnostics market in 2026, reflecting the substantial volume of patients requiring diagnostic evaluation and the need for timely identification of respiratory infections in clinical environments. Hospitals rely on influenza testing to support appropriate patient management, infection-control decisions, and differentiation of influenza from other respiratory illnesses. The importance of rapid diagnosis during periods of elevated respiratory disease activity further strengthens demand for reliable testing capabilities. Increasing pressure to improve clinical workflow efficiency and support appropriate treatment decisions is sustaining hospital adoption of influenza diagnostics.
Point-of-care testing (POCT) is expanding rapidly as healthcare providers seek diagnostic capabilities closer to patients and outside centralized laboratory environments. POCT enables faster access to influenza results, supporting timely clinical decisions in settings where immediate diagnostic information can improve workflow efficiency. Its growing relevance across outpatient care, urgent care, and other decentralized healthcare environments is supported by the broader shift toward accessible and rapid diagnostics. Increasing demand for convenient testing and reduced dependence on centralized laboratory processing is strengthening adoption of point-of-care influenza testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Test Type | RIDT, RT-PCR, Cell Culture, Others | RIDT | RIDT |
| End Use | Hospitals, POCT, Laboratories | Hospitals | POCT |
Competitive Landscape and Market Positioning
Leading companies in the influenza diagnostics market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Thermo Fisher Scientific Inc. (United States)
4. Becton Dickinson and Company (United States)
5. Hologic Inc. (United States)
6. QuidelOrtho Corporation (United States)
7. DiaSorin S.p.A. (Italy)
8. Sekisui Diagnostics LLC (United States)
9. Meridian Bioscience Inc. (United States)
10. bioMérieux SA (France)
Rapid infectious disease detection is shaping the influenza diagnostics market, particularly in response to seasonal outbreak management needs. The influenza diagnostics market is advancing through improved molecular testing and point-of-care technologies. Regulatory frameworks are influencing diagnostic accuracy and deployment standards. Continuous innovation is enhancing speed and reliability of test results.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Hologic Inc. (United States) | |||||||
| QuidelOrtho Corporation (United States) | |||||||
| DiaSorin S.p.A. (Italy) | |||||||
| Sekisui Diagnostics LLC (United States) | |||||||
| Meridian Bioscience Inc. (United States) | |||||||
| bioMérieux SA (France). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BD | Aug-23 | BD received FDA 510(k) clearance for a respiratory viral panel capable of detecting COVID-19, influenza A and B, and RSV in a single test. The approval strengthens BD’s multiplex diagnostic portfolio and enhances clinical efficiency by enabling consolidated respiratory pathogen detection within laboratory workflows. |
| Lucira Health | Feb-23 | Lucira Health, in collaboration with Pfizer Inc., received FDA emergency use authorization for an over-the-counter home diagnostic test capable of detecting influenza A and B alongside COVID-19. The approval expands at-home respiratory testing capabilities and increases accessibility of multiplex flu diagnostics for consumer healthcare applications. |
| Hologic Inc. | Oct-22 | Hologic Inc. launched its Aptima SARS-CoV-2/Flu multiplex diagnostic test across Europe and North America, enabling simultaneous detection of influenza viruses and COVID-19. The product strengthens molecular diagnostic offerings and supports broader adoption of integrated respiratory testing platforms in clinical laboratories. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Influenza Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Age Group | Pediatric, Adult, Geriatric |
| Sample Type | Nasal/Nasopharyngeal Swabs, Throat Swabs, Nasopharyngeal Aspirates, Other Specimens |
| Influenza Type | Influenza A, Influenza B, Influenza A & B Combined |
Influenza Diagnostics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Diagnostic Testing Adoption Roadmap |
|
| Point-of-Care Testing Expansion Strategy |
|
| Multiplex Diagnostic Technology Outlook |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the influenza diagnostics market?
How is the influenza diagnostics industry size expected to evolve during the forecast period?
How are seasonal influenza outbreaks influencing diagnostic purchasing patterns?
Why are government surveillance initiatives supporting sustained demand in the influenza diagnostics market?
Why does RIDT lead the influenza diagnostics market?
Why is POCT the fastest-growing end-use segment in the influenza diagnostics market?
Why does North America dominate the influenza diagnostics market?
What is fueling influenza diagnostics market growth in Asia Pacific?
Who are the leading players in the influenza diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization